TYK2/JAK1 Inhibitor AC-201 of Accropeutics Bioscience gained Human Research Ethics Committees (HREC) permission for Phase I

Accropeutics Bioscience announced that its oral small molecule TYK2/JAK1 inhibitor AC-201 has been approved by the Australian Human Research Ethics Committee to launch a clinical phase I trial in Australia.